DOSE REDUCTION OF A CANNABINOID CB1 RECEPTOR ANTAGONIST IN THE TREATMENT OF OVERWEIGHT OR OBESITY

摘要

O-(3-Piperidino-2-hydroxy-1-propyl)-nicotinic amidoxime or a pharmaceutically acceptable acid addition salt thereof is administered to patients suffering from overweight or obesity and treated with a cannabinoid CB1 receptor antagonist such as rimonabant to reduce the unfavourable psychiatric side effect of the latter.